Mckesson Corp

Company facts

Industry

Wholesale-Drugs, Proprietaries & Druggists' Sundries

Headquarters

Irving, Texas

Most recent report

10-Q, filed Nov 4, 2026

Incorporated

Delaware

Filings on record

1,002+ filings

On EDGAR

CIK 927653

Fiscal year ends

March

Filer status

Large accelerated filer

What to read: Sep 2026 10-Q

SECSift found 3 of 13 sections worth reading, with 0 positive, 7 notable, and 1 negative flags.

• Financial Statements (Item 1)

  Financial statements and notes show major debt increase, large buybacks, and opioid liability details.
  Notable

  • Apollo Funds invested $1.25B for a 13% stake in Medical-Surgical Solutions, classified as redeemable noncontrolling interest.
  • Net discrete tax benefit of $105M in Q2 FY2027 from releasing a valuation allowance in a foreign jurisdiction.

• Management's Discussion (Item 2)

  MD&A with major M&A, debt restructuring, segment separation, and opioid liability.
  Notable

  • Agreed to acquire 49% of Option Care Health for ~$1.4B; CD&R holds 51% majority.
  • Acquired Precision Medicine for $2.25B cash and controlling interest in Spectrum Vision for $525M.
  • Medical-Surgical subsidiaries raised $3.2B in new secured term loans; $1.0B revolver added.
  • Board raised quarterly dividend 15% to $0.94/share and authorized $5.0B new buyback.
  Negative

  • Total estimated opioid litigation liability stands at $5.2B as of September 30, 2026.

• Unregistered Sales and Repurchases (Item 2)

  Buyback pace accelerated sharply in Sept 2026; remaining authorization fell to $4.3B.
  Notable

  • Sept 2026 purchases include shares from May 2026 ASR program completion.

What changed: Sep 2026 vs. Jun 2026

About 12% of MCK's Sep 2026 10-Q is new information. 59 paragraphs were added, 173 changed, and 36 removed. Below are the most important lines SECSift identified.

• Item 2 99
• Item 1 88
• Item 6 3
• Item 5 2
• Item 4 1
• Item 1A 1